drugset
Drugs / bovine type I collagen
last change Apr 2026 re-read 3 minutes ago

bovine type I collagen

Protein / enzyme biologic

Developed for
diffuse scleroderma
Investigated by
Baltimore VA Medical Center · Beth Israel Medical Center · Georgetown University · Johns Hopkins University · Medical University of South Carolina · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
+5 more · Northwestern University · UTHSC · University of Alabama at Birmingham · University of California, Los Angeles · Wayne State University

Trials 1

today NCT00005675 · Ph 2
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 missed
Phase 2 NCT00005675 Apr 2000 → May 2005 diffuse scleroderma National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Completed Missed primary
Comparator or background therapy1 trial
Phase 1/2 NCT07530003 Comparator Apr 2026 → Dec 2027 expected — The First Affiliated Hospital of Xinxiang Medical College Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as bovine type I collagen ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005675 ↗
1

NCT07530003 ↗
Modality Protein / enzyme biologic “bovine type I collagen” NCT07530003 ↗
Route Oral “Participants will receive oral bovine type I collagen (CI) daily for 15 months” NCT00005675 ↗